Loading company…
Neos Therapeutics, Inc. of Grand Prairie, US develops and sells treatments for central nervous system disorders.
Founded in 2008 and headquartered in Grand Prairie, US, Neos Therapeutics, Inc. develops and commercializes therapeutics for central nervous system disorders such as ADHD and major depressive disorder. Its product EXXUA is designed for ADHD, and the company reported revenue of USD 64.65 mn and EBITDA of USD -6.22 mn in 2019. It raised USD 40.00 mn in its latest round, completed an IPO in July 2015 that generated USD 72 mn, and is expected to merge with Aytu BioScience, Inc., a deal slated to finalize in 2021. It is listed at the Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in